Stockscreener 앱 받기
27.46
1.78%
0.48
시간 외 거래:
27.46
전일 마감가:
$26.98
열려 있는:
$27.605
하루 거래량:
995.59K
Relative Volume:
0.98
시가총액:
$2.08B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-36.61
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
+3.19%
1개월 성능:
-10.14%
6개월 성능:
-37.77%
1년 성능:
+28.26%
1일 변동 폭
$27.10
$28.07
1주일 범위
$26.05
$28.07
52주 변동 폭
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
27.46 | 2.08B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems - Benzinga
Veracyte chief commercial officer sells shares for $76,409 By Investing.com - Investing.com Canada
Veracyte chief commercial officer sells shares for $76,409 - Investing.com Australia
Cathie Wood’s ARK buys Veracyte, sells AvidXchange and 3D Systems stock - Investing.com
Insider Selling: John Leite Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Top Companies in the NASDAQ Veracyte and Others by Kalkine - Kalkine Media
Two Sigma Advisers LP Cuts Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte at Jefferies Global Healthcare Conference: Strategic Growth and Innovation - Investing.com Nigeria
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia
Veracyte (VCYT) Shares Pulled Back Despite Beating Expectations - MSN
Veracyte at William Blair Growth Stock Conference: Strategic Insights Unveiled - Investing.com Canada
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO - MSN
Veracyte, Inc. (NASDAQ:VCYT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research - BioSpace
Veracyte (VCYT) Showcases Findings at ASCO Annual Meeting | VCYT Stock News - GuruFocus
Veracyte to present multiple abstracts at ASCO - TipRanks
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Shares Gap Down to $26.74 on May 28 - GuruFocus
Veracyte: Upgrading To Neutral (NASDAQ:VCYT) - Seeking Alpha
Captrust Financial Advisors Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Scotiabank maintains Veracyte stock with $44 target - Investing.com
Scotiabank maintains Veracyte stock with $44 target By Investing.com - Investing.com India
Deutsche Bank AG Has $3.22 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte to Participate in Upcoming Investor Conferences | VCYT Stock News - GuruFocus
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally? - Zacks Investment Research
BNP Paribas Financial Markets Sells 55,684 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
William Blair Estimates Veracyte’s Q2 Earnings (NASDAQ:VCYT) - Defense World
Stifel Financial Corp Sells 2,211 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Veracyte (VCYT) and Inotiv (NOTV) - The Globe and Mail
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
1.06%
자본화:
|
볼륨(24시간):